SK Biopharmaceuticals Co., Ltd.
326030
Classement en actions
#3730
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
Prix de l'action
$56.51
Capitalisation boursière
$4.43B
Changement (1 jour)
0.00%
Changement (1 an)
-25.24%
Pays
KR
Échange SK Biopharmaceuticals Co., Ltd. (326030)
Catégorie
Healthcare
Historique du prix de l'action pour SK Biopharmaceuticals Co., Ltd. (326030)
Prix de clôture le plus élevé : $51.70 le 2026-10-01
Prix de clôture le plus bas : $157.85 le 2020-07-01
Prix de clôture le plus bas : $157.85 le 2020-07-01
Historique du prix de l'action de SK Biopharmaceuticals Co., Ltd. de 2020 à 2026
Performance annuelle du prix de l'action
| Année | Performance |
|---|---|
| 2026 (TTM) | -22.47% |
| 2025 | 24.61% |
| 2024 | 2.56% |
| 2023 | 25.24% |
| 2022 | -33.05% |
| 2021 | -47.19% |
| 2020 | 0.00% |
Prix de l'action pour des entreprises similaires ou concurrentes
| Entreprise | Prix de l'action | Variation 1a% | Pays |
|---|---|---|---|
| $536.13 | 25.72% |
US
|
|
| $200.12 | 645.31% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $880.01 | 8.09% |
NL
|
